Pioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/in Artificial Intelligence, Preclinical Research/by MaxIn The UK, Regulators Move Towards a New Era of Personalized Cancer Treatment
/in Expert Insights/by MaxCRISPR Strikes Again: Fat Cells Starve Tumors,A Revolutionary Approach to Cancer Treatment
/in CRISPR, Preclinical Research/by MaxPhase 1 Clinical Trial Recruiting: HLD-0915 a RIPTAC (Regulated Induced Proximity Targeting Chimera)
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CRB-701, A Promising Antibody-Drug Conjugate Targeting Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxLY4052031 and LY4101174: Other 2 Nectin-4-Targeting Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 3/2026 January 18, 2026
- A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer January 16, 2026
- SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors January 16, 2026
- UPDATE: SECuRE Trial Phase 2 Shows 67% PSA50 Response in Heavily Pre-Treated mCRPC January 16, 2026